Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × Valacyclovir × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Leukemia 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1 Adenocarcinoma 1

Interventions

Temozolomide 136 Bevacizumab 75 Radiotherapy 67 Magnetic Resonance Spectroscopy 21 Irinotecan 18 pembrolizumab 16 Radiation 16 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 11 Nivolumab 10 Erlotinib Hydrochloride 10 sargramostim 9 Thalidomide 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Specimen Handling 8 Carboplatin 8 Cilengitide 7 Sunitinib 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiosurgery 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Filgrastim 5 Etoposide 5 Celecoxib 5 Topotecan 4 Tamoxifen 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed

52 enrolled 10 charts

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡